Company Overview and News

Scomi shares in focus as merger proposal fell through

KUALA LUMPUR: Shares of Scomi Group Bhd fell as much as 11% in early trade Friday after its three-way merger proposal fell through.

Merger of Scomi Energy fails

According to a market observer, Scomi Energy shareholders’ interest was considerably boosted with crude hitting its recent highs since 2015. “They prefer to have Scomi Energy stay as a listed entity,” a remisier said

Breakfast briefing: Wednesday, October 11

MarketWatch: The Dow Jones Industrial Average hit a record high on Tuesday, helped by a surge in Wal-Mart Stores, while Amazon and Facebook lost ground and investors focused on upcoming quarterly reports. The DJIA rose 0.31% to 22,830.68 points, a record-high close, the S&P 500 gained 0.23% to 2,550.64 and the Nasdaq added 0.11% to 6,587.25. - Reuters

Breakfast briefing: Friday, August 18

MarketWatch: US stocks sold off on Thursday, with the S&P 500 recording its biggest daily percentage drop in three months as escalating worries about the Trump administration's ability to push through its economic agenda rattled investors. The DJIA ended down 274.14 points, or 1.24%, to 21,750.73, the S&P 500 lost 38.1 points, or 1.54%, to 2,430.01 and the Nasdaq dropped 123.20 points, or 1.94%, to 6,221.

For the record

IN our story “Auditors raise doubts on Scomi’s business ability due to ongoing disputes” on July 25, the company is Scomi Engineering Bhd and not as published.

KL Monorail dispute may hurt Scomi Eng’s going concern ability

The Scomi Engineering group has yet to secure further extension from the lenders who have provided project financing for the KL Monorail expansion project, says KPMG.

Breakfast briefing: Friday, July 7

MarketWatch: US stocks were sharply lower on Thursday after disappointing labor market data clashed with the possibility of a more hawkish Federal Reserve, while rising tensions in the Korean peninsula providing additional pressure. The DJIA fell 158.13 points, or 0.74%, to 21,320.04, the S&P 500 lost 22.79 points, or 0.94%, to 2,409.75 and the Nasdaq dropped 61.39 points, or 1%, to 6,089.46.  - Reuters

Scomi unit files suit over statements by Prasarana, Rapid Rail

After all the 12 four-car trains are in operation, the 2-car trains are supposed to be decommissioned.

13 safety-critical modifications needed on monorail trains

2017-06-12 themalaymailonline
Zohari said Rapid Rail would only redeploy the trains to revenue service when they were certified safe by Scomi. — Picture courtesy of WikipediaKUALA LUMPUR, June 12 — Rapid Rail Sdn Bhd and Scomi Engineering Berhad have identified 13 safety-critical modifications that need to be carried out on the four-car monorail trains before returning them to service.

Monorail trains built for Prasarana are ‘fit for operation’ - Scomi

Scomi Engineering says that prior to the revenue service, its trains underwent rigorous validation process, design reviews and endurance tests.

Prasarana, Scomi now clash over the third supplemental contract

The contract central to the Prasarana-STP dispute involves the upgrading of the Kuala Lumpur monorail stations and the electrical and mechanical system, the construction of a new depot, and delivery of 12 sets of new four-car trains.

Scomi to ensure on the dot delivery of four-car trains

Rapid Rail operates the KL Monorail Line and is a subsidiary of Prasarana. Prasarana and Scomi Engineering had been locked in dispute over the expansion of the KL Monorail project and in March, both parties inked a third supplemental contract to resolve the issue.

Mumbai: Financial crisis of contract company hits Monorail operations, says MMRDA

Mumbai: The Monorail which will run from Chembur to Jacob Circle has been delayed and citizens are clueless the commencement of this project.

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...